INTRA-CELLULAR THERAPI

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

03 янв 2022 15:01:00 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 янв 2022 07:00:01 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults

20 дек 2021 05:47:22 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies Mourns the Passing of Director, Dr. Richard Lerner

06 дек 2021 15:01:00 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update

09 ноя 2021 06:30:01 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host Third Quarter 2021 Financial Results Conference Call and Webcast

02 ноя 2021 07:00:03 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces Amended Start Time to Virtual Event on Wednesday, October 20

18 окт 2021 07:00:00 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host a Virtual Event to Feature Highlights of Several of its Development Programs

08 окт 2021 07:00:00 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry

27 сен 2021 06:30:00 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at the 2021 Cantor Virtual Global Healthcare Conference

22 сен 2021 07:00:01 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces Publications Highlighting Beneficial Effects of Phosphodiesterase Type I Inhibition with Lenrispodun (ITI-214) on Cardiovascular Function in Patients with Heart Failure and in Models of Accelerated Aging

20 сен 2021 06:30:00 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at the Canaccord Genuity 41st Annual Growth Conference

10 авг 2021 07:00:02 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update

09 авг 2021 06:30:00 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host Second Quarter 2021 Financial Results Conference Call and Webcast

02 авг 2021 07:00:02 Источник Nasdaq GlobeNewswire

CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology

07 июн 2021 07:00:02 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences

26 май 2021 07:00:02 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update

10 май 2021 06:30:00 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences

05 май 2021 07:00:01 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host First Quarter 2021 Financial Results Conference Call and Webcast

04 май 2021 07:00:01 Источник Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression

03 май 2021 06:30:00 Источник Nasdaq GlobeNewswire